United Kingdom’s NHS and several cancer charities are looking at whether a cannabis-based mouth spray can treat brain tumors and help the patients. The medicine, adequately used in treating multiple sclerosis, was seen to be fair in blend in with chemotherapy, with the likelihood to extend perseverance, in phase I trial in glioblastomas as of late.
“The latest three-year phase II trial (ARISTOCRAT), financed by The Brain Tumor Charity and formed by the Cancer Research UK Clinical Trials Unit at the University of Birmingham, is a direct result of begin choosing more than 230 patients across all UK nations in mid 2022, subject to sufficient funds being raised”, examined the news release by Leeds University.
Professor Susan Short, the standard investigator on the new trial and Professor of Clinical Oncology and Neuro-Oncology at Leeds said, “The treatment of glioblastomas remains incredibly testing. In reality, even with surgery, radiotherapy and chemotherapy, for all intents and purposes these brain tumors re-create inside a year, and unfortunately there are not a lot of choices for patients once this occurs”.
Susan also added, “Glioblastoma brain tumors have been shown to have receptors to cannabinoids on their cell surfaces, and exploration office studies on glioblastoma cells have shown these drugs may direct tumor growth and capacity honorably when used with temozolomide”.